 Shares of Alkermes NASDAQ:ALKS rose 2.5 in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share decreased 33.33 year over year to 0.06, which beat the estimate of 0.01.Revenue of 247,529,000 decreased by 11.56 from the same period last year, which beat the estimate of 232,750,000.Outlook The upcoming fiscal years EPS expected to be between 0.00 and 0.19.The upcoming fiscal years revenue expected to be between 965,000,000 and 1,005,000,000.How To Listen To The Conference Call Date: Jul 29, 2020View more earnings on ALKSTime: 08:00 AMET Webcast URL: Stock Performance 52-week high: 23.50Companys 52-week low was at 11.98Price action over last quarter: Up 47.19Company Description Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.See more from Benzinga Chefs Warehouse: Q2 Earnings Insights Recap: Silicon Laboratories Q2 Earnings Recap: Axalta Coating Systems Q2 EarningsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 